Jackie Coleman Daigle, MD
Family Medicine · New Orleans, LANPI 1063584928
Payments from drug & device makers
Across 265 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$682
- Pfizer$451
- Lilly USA, LLC$427
- GSK$283
- Gilead$268
- Novo Nordisk$247
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,580100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $682 |
| Pfizer | 32 | $451 |
| Lilly USA, LLC | 25 | $427 |
| GSK | 16 | $283 |
| Gilead | 12 | $268 |
| Novo Nordisk | 15 | $247 |
| Amgen | 14 | $222 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $181 |
| Supernus Pharmaceuticals, Inc. | 7 | $180 |
| Exact Sciences | 8 | $172 |
| AstraZeneca | 10 | $162 |
| Boehringer Ingelheim | 8 | $138 |
| Teva Pharmaceuticals USA, Inc. | 8 | $130 |
| Amneal Pharmaceuticals LLC | 8 | $114 |
| Otsuka America Pharmaceutical, Inc. | 5 | $104 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $99 |
| Abbott | 4 | $87 |
| Merck | 5 | $72 |
| Scilex Pharmaceuticals Inc. | 4 | $72 |
| Amarin Pharma, Inc. | 3 | $52 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $47 |
| Shire North American Group Inc | 2 | $40 |
| Johnson & Johnson(2 entities) | 2 | $40 |
| Adlon Therapeutics L.p. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Dexcom, Inc. | 1 | $26 |
| Viatris Specialty LLC | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Eisai Inc. | 1 | $12 |
How this compares
$4,580 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 104 | $132,465 |
| OzempicSemaglutide | 78 | $99,667 |
| MounjaroTirzepatide | 90 | $99,178 |
| EliquisApixaban | 93 | $75,664 |
| TrulicityDulaglutide | 66 | $70,327 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $35,986 |
| XareltoRivaroxaban | 29 | $32,150 |
| LinzessLinaclotide | 32 | $31,560 |
| VraylarCariprazine Hcl | 16 | $24,790 |
| RybelsusSemaglutide | 14 | $21,651 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $19,738 |
| MyrbetriqMirabegron | 25 | $13,103 |
| TrintellixVortioxetine Hydrobromide | 24 | $11,063 |
| FarxigaDapagliflozin Propanediol | 13 | $8,720 |
| Fentanyl | 12 | $6,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $427 | $169,505156 claims |
| Boehringer IngelheimJardiance | $138 | $132,465104 claims |
| Novo NordiskOzempic, Rybelsus | $247 | $121,31892 claims |
| PfizerEliquis, Prempro | $451 | $81,292116 claims |
| AbbVieLinzess, Vraylar | $682 | $56,35048 claims |
| GSKTrelegy Ellipta | $283 | $35,98650 claims |
| Johnson & JohnsonXarelto | $40 | $32,15029 claims |
| AstraZenecaFarxiga, Symbicort | $162 | $13,47234 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $181 | $11,06324 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $114 | $1,714186 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in New Orleans
- Stephen JonesNew Orleans$513K
- Kristen ThomasNew Orleans$361K
- Ibrahim ZeinatyNew Orleans$13K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.